CHMP Recommended Teclistamab Indication Extension
The European regulator backed the expansion of teclistamab for adult patients with relapsed or refractory multiple myeloma.
Updated on Sept. 18, 2026 in Cancer
Live Poll
Do you trust pharmaceutical companies to prioritize affordable access to new cancer therapies?
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommended an indication extension for TECVAYLI. This decision applies to adult patients who have received at least one prior therapy for relapsed or refractory multiple myeloma.
Why it matters
Patients with multiple myeloma frequently experience relapse after first-line treatment. The recommendation aims to address the urgent need for effective immunotherapy options in earlier stages of the disease.
In the MajesTEC-9 study, 65.9% of patients on teclistamab achieved a complete response or better, compared to 16.8% of those on standard of care. The median treatment duration was 13.1 months for the teclistamab group versus 7.0 months for the standard care arm.
The players
European Medicines Agency
This is the decentralized agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
Committee for Medicinal Products for Human Use
This is the committee within the European Medicines Agency responsible for preparing opinions on questions concerning medicines for human use.
The details
Teclistamab is a subcutaneous bispecific antibody that redirects T-cells through BCMA and CD3 targets to treat cancer. The study compared this monotherapy against standard regimens including pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone.
Timeline
August 2022: Initial European Commission approval for teclistamab.
August 2023: European Commission approval for reduced dosing frequency.
August 2026: European Commission approval for teclistamab combined with daratumumab.
September 18, 2026: CHMP recommended the indication extension for TECVAYLI.
The Big Picture
This recommendation marks a significant clinical progression from the August 2022 EC initial approval for teclistamab.
If approved, this extension will provide adult patients who have failed one prior therapy with a new subcutaneous bispecific antibody option. Patients should consult their oncologists to determine if this immunotherapy aligns with their specific treatment history and disease profile.
The takeaway
Teclistamab has demonstrated a 40% reduction in the risk of death compared to traditional treatment regimens. This data underscores the potential for bispecific antibodies to significantly alter outcomes for those managing relapsed multiple myeloma.
Further reading
For more information on current treatment standards and research developments, visit our Cancer section.
More information
Read the Summary of Product Characteristics for complete details on the therapy.
Live Poll
Do you trust pharmaceutical companies to prioritize affordable access to new cancer therapies?
